Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S M Hwang

Showing results (101-110 of 122) with videos related to

Pageof 13
Sort By:
Journal of Medicinal Chemistry|October 16, 1992
Design and synthesis of a C7 mimetic for the predicted gamma-turn conformation found in several constrained RGD antagonistsJ F Callahan, J W Bean, J L Burgess, et al.
Clinical Genetics|June 12, 2014
Identification of novel mutations in the VPS33B gene involved in arthrogryposis, renal dysfunction, and cholestasis syndromeS H Seo, S M Hwang, J M Ko, et al.
Journal of Medicinal Chemistry|March 18, 1994
Conformationally constrained peptides and semipeptides derived from RGD as potent inhibitors of the platelet fibrinogen receptor and platelet aggregationF E Ali, D B Bennett, R R Calvo, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|March 30, 2001
Human osteoclast cathepsin K is processed intracellularly prior to attachment and bone resorptionR A Dodds, I E James, D Rieman, et al.
The Journal of Biological Chemistry|June 27, 1997
Cloning and characterization of a novel integrin beta3 subunitC S Kumar, I E James, A Wong, et al.
The Journal of Pharmacology and Experimental Therapeutics|May 16, 1998
Binding of [3H]-SK&F 107260 and [3H]-SB 214857 to purified integrin alphaIIbbeta3: evidence for a common binding site for cyclic arginyl-glycinyl-aspartic acid peptides and nonpeptidesA Wong, S M Hwang, K Johanson, et al.
Bioorganic & Medicinal Chemistry Letters|July 16, 1999
Orally bioavailable nonpeptide vitronectin receptor antagonists containing 2-aminopyridine arginine mimeticsR M Keenan, W H Miller, L S Barton, et al.
Journal of Medicinal Chemistry|July 18, 1997
Discovery of potent nonpeptide vitronectin receptor (alpha v beta 3) antagonistsR M Keenan, W H Miller, C Kwon, et al.
The Journal of Biological Chemistry|January 20, 2001
Potent and selective cathepsin L inhibitors do not inhibit human osteoclast resorption in vitroI E James, R W Marquis, S M Blake, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|February 24, 2001
Antagonism of the osteoclast vitronectin receptor with an orally active nonpeptide inhibitor prevents cancellous bone loss in the ovariectomized ratM W Lark, G B Stroup, R A Dodds, et al.
Pageof 13

Showing results (101-110 of 122) with videos related to

Sort By:
Pageof 13
Journal of Medicinal Chemistry|October 16, 1992
Design and synthesis of a C7 mimetic for the predicted gamma-turn conformation found in several constrained RGD antagonistsJ F Callahan, J W Bean, J L Burgess, et al.
Clinical Genetics|June 12, 2014
Identification of novel mutations in the VPS33B gene involved in arthrogryposis, renal dysfunction, and cholestasis syndromeS H Seo, S M Hwang, J M Ko, et al.
Journal of Medicinal Chemistry|March 18, 1994
Conformationally constrained peptides and semipeptides derived from RGD as potent inhibitors of the platelet fibrinogen receptor and platelet aggregationF E Ali, D B Bennett, R R Calvo, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|March 30, 2001
Human osteoclast cathepsin K is processed intracellularly prior to attachment and bone resorptionR A Dodds, I E James, D Rieman, et al.
The Journal of Biological Chemistry|June 27, 1997
Cloning and characterization of a novel integrin beta3 subunitC S Kumar, I E James, A Wong, et al.
The Journal of Pharmacology and Experimental Therapeutics|May 16, 1998
Binding of [3H]-SK&F 107260 and [3H]-SB 214857 to purified integrin alphaIIbbeta3: evidence for a common binding site for cyclic arginyl-glycinyl-aspartic acid peptides and nonpeptidesA Wong, S M Hwang, K Johanson, et al.
Bioorganic & Medicinal Chemistry Letters|July 16, 1999
Orally bioavailable nonpeptide vitronectin receptor antagonists containing 2-aminopyridine arginine mimeticsR M Keenan, W H Miller, L S Barton, et al.
Journal of Medicinal Chemistry|July 18, 1997
Discovery of potent nonpeptide vitronectin receptor (alpha v beta 3) antagonistsR M Keenan, W H Miller, C Kwon, et al.
The Journal of Biological Chemistry|January 20, 2001
Potent and selective cathepsin L inhibitors do not inhibit human osteoclast resorption in vitroI E James, R W Marquis, S M Blake, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|February 24, 2001
Antagonism of the osteoclast vitronectin receptor with an orally active nonpeptide inhibitor prevents cancellous bone loss in the ovariectomized ratM W Lark, G B Stroup, R A Dodds, et al.
Pageof 13